Back to portfolio
Giiant Pharma Inc. (www.giiant.com) is a Montreal-based preclinical-stage biotech company developing gut-restricted, small molecule, tissue-specific drug therapeutics for the treatment of of inflammatory bowel diseases (IBD) including moderate-to-severe ulcerative colitis. Precision Delivery remains central for the development of new drug therapeutics, with limited systemic exposure for safer profile and maximal local action to improve IBD patient care. The company intends to meet this need through a prodrug activated locally by the colonic microbiome, in order to limit the systemic exposure of the active form of phosphodiestherase-4 enzyme inhibitors. This approach proposes to improve the local treatment of IBD and thus make it safer.
In May of 2021, Giiant Pharma Inc. announced the closing of CAD$ 13.5M million in Seed financing for which AmorChem participated. True to its mission of fostering biotech startups in their transformation into next gen companies, the fund provided expert leadership to this portfolio company.
